BE1011382A5 - Methodes de prevention du cancer du sein. - Google Patents

Methodes de prevention du cancer du sein. Download PDF

Info

Publication number
BE1011382A5
BE1011382A5 BE9700865A BE9700865A BE1011382A5 BE 1011382 A5 BE1011382 A5 BE 1011382A5 BE 9700865 A BE9700865 A BE 9700865A BE 9700865 A BE9700865 A BE 9700865A BE 1011382 A5 BE1011382 A5 BE 1011382A5
Authority
BE
Belgium
Prior art keywords
sep
effective dose
manufactured product
breast cancer
day
Prior art date
Application number
BE9700865A
Other languages
English (en)
French (fr)
Inventor
Jay Cohen Frederic
Ellen Glusman Joan
Keith Knickerbocker Ronald
Thomas Nickelsen Nikolaus
Janine Scott Teri
Stephen Eckert Robert
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE1011382(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of BE1011382A5 publication Critical patent/BE1011382A5/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE9700865A 1996-10-30 1997-10-29 Methodes de prevention du cancer du sein. BE1011382A5 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10

Publications (1)

Publication Number Publication Date
BE1011382A5 true BE1011382A5 (fr) 1999-08-03

Family

ID=27268608

Family Applications (2)

Application Number Title Priority Date Filing Date
BE9700865A BE1011382A5 (fr) 1996-10-30 1997-10-29 Methodes de prevention du cancer du sein.
BE9700864A BE1011381A5 (fr) 1996-10-30 1997-10-29 Ameliorations concernant la prophylaxie du cancer du sein.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BE9700864A BE1011381A5 (fr) 1996-10-30 1997-10-29 Ameliorations concernant la prophylaxie du cancer du sein.

Country Status (43)

Country Link
US (2) US6303634B1 (enExample)
EP (3) EP0839532B1 (enExample)
JP (2) JPH10147529A (enExample)
CN (2) CN1182590A (enExample)
AP (1) AP971A (enExample)
AR (2) AR010538A1 (enExample)
AT (2) ATE338551T1 (enExample)
AU (3) AU5005697A (enExample)
BE (2) BE1011382A5 (enExample)
BG (1) BG63841B1 (enExample)
BR (1) BR9712703A (enExample)
CA (2) CA2219070C (enExample)
CH (2) CH693820A5 (enExample)
CZ (2) CZ300261B6 (enExample)
DE (2) DE69721692T2 (enExample)
DK (2) DK1369115T3 (enExample)
EA (2) EA006083B1 (enExample)
EE (1) EE03663B1 (enExample)
ES (4) ES2135343A1 (enExample)
FR (2) FR2755014B1 (enExample)
GB (3) GB2318734B (enExample)
GE (1) GEP20032910B (enExample)
GR (2) GR1003189B (enExample)
HU (2) HUP9701777A3 (enExample)
IE (2) IE970772A1 (enExample)
IL (2) IL122026A0 (enExample)
IS (1) IS5035A (enExample)
IT (2) ITMI972434A1 (enExample)
LU (2) LU90157B1 (enExample)
LV (1) LV12353B (enExample)
MY (1) MY121623A (enExample)
NL (2) NL1007386C2 (enExample)
NO (2) NO322468B1 (enExample)
NZ (1) NZ329042A (enExample)
PT (2) PT1369115E (enExample)
RO (1) RO120813B1 (enExample)
SG (2) SG83672A1 (enExample)
SI (3) SI1369115T1 (enExample)
SK (1) SK287047B6 (enExample)
TR (1) TR199900951T2 (enExample)
UA (1) UA46762C2 (enExample)
WO (2) WO1998018325A1 (enExample)
YU (1) YU42397A (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI982733L (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
EP1401446B1 (en) 2001-05-22 2005-02-09 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用
MX2023013107A (es) * 2023-11-06 2025-06-02 Centro De Investig Y De Estudios Avanzados Del I P N Composiciones sinergicas de loratadina-raloxifeno-sorafenib para el tratamiento de cancer hepatico.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0652004A1 (en) * 1993-10-15 1995-05-10 Eli Lilly And Company Methods for treating resistant neoplasms
EP0674903A1 (en) * 1994-03-02 1995-10-04 Eli Lilly And Company Raloxifene for inhibiting bone loss and lowing serum cholesterol
EP0680758A1 (en) * 1994-05-05 1995-11-08 Eli Lilly And Company Pharmaceutical compositions containing tamoxifen or analogs and raloxifene or analogs
WO1996022771A1 (en) * 1995-01-25 1996-08-01 Eli Lilly And Company Methods of inhibiting environmental estrogens
WO1997035571A1 (en) * 1996-03-26 1997-10-02 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
IL112746A (en) * 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0652004A1 (en) * 1993-10-15 1995-05-10 Eli Lilly And Company Methods for treating resistant neoplasms
EP0674903A1 (en) * 1994-03-02 1995-10-04 Eli Lilly And Company Raloxifene for inhibiting bone loss and lowing serum cholesterol
EP0680758A1 (en) * 1994-05-05 1995-11-08 Eli Lilly And Company Pharmaceutical compositions containing tamoxifen or analogs and raloxifene or analogs
WO1996022771A1 (en) * 1995-01-25 1996-08-01 Eli Lilly And Company Methods of inhibiting environmental estrogens
WO1997035571A1 (en) * 1996-03-26 1997-10-02 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"FIRST PHASE III RESULTS WITH RALOXIFENE", DATABASE FILE 129, PHIND; DIALOG INFORMATION SERVICES; AN=540210, 13 June 1997 (1997-06-13), pages 17, XP002054373 *
"MARKET ANALYSIS FROM DECISION RESOURCES: BREAST CANCER", DATABASE FILE 187, FDC REPORTS; DIALOG INFORMATION SERVICES, AN=1249, vol. 1, no. 4, 1 April 1996 (1996-04-01), XP002054375 *
M.A. ANZANO ET AL.: "CHEMOPREVENTION OF MAMMARY CARCINOGENESIS IN THE RAT: COMBINED USE OF RALOXIFENE AND 9-CIS-RETINOIC ACID", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 88, no. 2, January 1996 (1996-01-01), pages 123 - 125, XP002054376 *
V.C. JORDAN ET AL.: "ALTERNATE ANTIESTROGENS AND APPROACHES TO THE PREVENTION OF BREAST CANCER", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 58, no. S.22, 1995, pages 51 - 57, XP002054374 *

Also Published As

Publication number Publication date
CZ341297A3 (cs) 1998-05-13
LU90157B1 (fr) 1998-06-02
GEP20032910B (en) 2003-03-25
MX9708341A (es) 1998-08-30
AU4364897A (en) 1998-05-07
DK1369115T3 (da) 2007-01-02
AU5005197A (en) 1998-05-22
YU42397A (sh) 2000-10-30
EA002054B1 (ru) 2001-12-24
NO322468B1 (no) 2006-10-09
EP0839532A1 (en) 1998-05-06
EE9900162A (et) 1999-12-15
HUP9701777A2 (hu) 1999-06-28
DE69721692D1 (de) 2003-06-12
ES2271476T3 (es) 2007-04-16
SI20107A (sl) 2000-06-30
LV12353A (lv) 1999-10-20
AU5005697A (en) 1998-05-22
SG72765A1 (en) 2000-05-23
US6303634B1 (en) 2001-10-16
JPH10147529A (ja) 1998-06-02
CH691847A5 (fr) 2001-11-15
DK0839532T3 (da) 2003-08-25
PT1369115E (pt) 2006-12-29
ES2135342B1 (es) 2000-05-16
AU731388B2 (en) 2001-03-29
NO974972D0 (no) 1997-10-28
AR013864A1 (es) 2001-01-31
CA2219070C (en) 2007-12-18
JPH10147530A (ja) 1998-06-02
CZ300261B6 (cs) 2009-04-01
ES2197312T3 (es) 2004-01-01
IL122025A0 (en) 1998-03-10
ES2135343A1 (es) 1999-10-16
NO974972L (no) 1998-05-04
BR9712703A (pt) 1999-10-26
GB2318734B (en) 1999-12-01
WO1998018449A1 (en) 1998-05-07
IS5035A (is) 1999-04-27
FR2756490B1 (fr) 2003-06-20
NL1007387C2 (nl) 1998-05-14
EP1369115B1 (en) 2006-09-06
GR970100408A (el) 1998-06-30
FR2756490A1 (fr) 1998-06-05
BE1011381A5 (fr) 1999-08-03
ATE338551T1 (de) 2006-09-15
UA46762C2 (uk) 2002-06-17
ATE239475T1 (de) 2003-05-15
EA199900431A1 (ru) 1999-10-28
NZ329042A (en) 1999-08-30
CN1182590A (zh) 1998-05-27
TR199900951T2 (xx) 1999-07-21
GB2318733A (en) 1998-05-06
HUP9701778A2 (hu) 1999-01-28
AU4364797A (en) 1998-05-07
EA200100716A1 (ru) 2002-06-27
PT839532E (pt) 2003-09-30
DE69736644D1 (de) 2006-10-19
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29
NO974973D0 (no) 1997-10-28
AP9901494A0 (en) 1999-03-31
EP1369115A1 (en) 2003-12-10
CH693820A5 (fr) 2004-02-27
IL122026A0 (en) 1998-03-10
ES2135342A1 (es) 1999-10-16
GR1003189B (el) 1999-09-01
GB9722801D0 (en) 1997-12-24
IE970773A1 (en) 2000-02-09
EE03663B1 (et) 2002-04-15
EP0839533A1 (en) 1998-05-06
DE69721692T2 (de) 2004-03-25
HUP9701777A3 (en) 1999-07-28
SK55999A3 (en) 2000-06-12
LV12353B (en) 2000-02-20
IE970772A1 (en) 2000-02-09
DE69736644T2 (de) 2007-10-25
NL1007386C2 (nl) 1998-05-14
AP971A (en) 2001-05-30
WO1998018325A1 (en) 1998-05-07
SI1369115T1 (sl) 2006-12-31
GB2318734A (en) 1998-05-06
SK287047B6 (sk) 2009-10-07
BG103369A (en) 2000-05-31
HK1010495A1 (en) 1999-06-25
FR2755014A1 (fr) 1998-04-30
US20020019418A1 (en) 2002-02-14
EA006083B1 (ru) 2005-08-25
IL122025A (en) 2003-01-12
EP0839532B1 (en) 2003-05-07
MY121623A (en) 2006-02-28
CZ341197A3 (cs) 1998-05-13
GR970100409A (el) 1998-06-30
FR2755014B1 (fr) 1999-02-05
CA2219070A1 (en) 1998-04-30
LU90158B1 (fr) 1998-06-02
MX9708340A (es) 1998-08-30
ITMI972433A1 (it) 1999-04-29
GB9911557D0 (en) 1999-07-21
AR010538A1 (es) 2000-06-28
HUP9701778A3 (en) 1999-06-28
SG83672A1 (en) 2001-10-16
BG63841B1 (bg) 2003-03-31
GB9722796D0 (en) 1997-12-24
SI0839532T1 (en) 2003-10-31
ITMI972434A1 (it) 1999-04-29
IT1298470B1 (it) 2000-01-10
CN1182591A (zh) 1998-05-27
RO120813B1 (ro) 2006-08-30
CA2219377A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
CH693820A5 (fr) Utilisation de raloxifen pour la prévention du cancer du sein.
AU712800B2 (en) Method of increasing testosterone
JPH06234632A (ja) ベンゾチオフェン類を含有する医薬組成物
AU2004231254B2 (en) Methods of preventing breast cancer
US20040167170A1 (en) Methods of preventing breast cancer
RU2203060C2 (ru) Способ профилактики рака молочной железы
IL152080A (en) Use of raloxifene or pharmaceutically acceptable salts or solvates thereof in the preparation of a medicament for preventing breast cancer
MXPA97008341A (en) Procedures to prevent the cancer of m
HK1010493A (en) Methods of preventing breast cancer by the administration of raloxifene
JP2000503995A (ja) 筋腱膜線維腫（類腱腫）を抑制する方法
KR19980033283A (ko) 유방암의 예방 방법

Legal Events

Date Code Title Description
RE Patent lapsed

Effective date: 20081031